Heron Therapeutics Inc (NASDAQ:HRTX) was the target of some unusual options trading activity on Thursday. Stock traders bought 4,937 call options on the stock. This is an increase of 1,784% compared to the average volume of 262 call options.

Several research firms have recently commented on HRTX. Cantor Fitzgerald set a $31.00 price target on shares of Heron Therapeutics and gave the company a “buy” rating in a research note on Friday. ValuEngine raised shares of Heron Therapeutics from a “sell” rating to a “hold” rating in a research note on Sunday, December 31st. Leerink Swann began coverage on shares of Heron Therapeutics in a research note on Tuesday, January 2nd. They set an “outperform” rating and a $22.00 price target on the stock. Mizuho began coverage on shares of Heron Therapeutics in a research note on Tuesday, September 26th. They set a “buy” rating and a $28.00 price target on the stock. Finally, BidaskClub raised shares of Heron Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, December 20th. Two investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. Heron Therapeutics has a consensus rating of “Buy” and an average target price of $28.82.

Hedge funds have recently made changes to their positions in the business. Legal & General Group Plc boosted its stake in Heron Therapeutics by 26.6% in the second quarter. Legal & General Group Plc now owns 11,354 shares of the biotechnology company’s stock valued at $157,000 after acquiring an additional 2,383 shares during the last quarter. Quantbot Technologies LP boosted its stake in Heron Therapeutics by 2,619.6% in the second quarter. Quantbot Technologies LP now owns 12,483 shares of the biotechnology company’s stock valued at $172,000 after acquiring an additional 12,024 shares during the last quarter. Trexquant Investment LP bought a new position in Heron Therapeutics in the third quarter valued at approximately $206,000. Jane Street Group LLC bought a new position in Heron Therapeutics in the third quarter valued at approximately $223,000. Finally, HighTower Advisors LLC boosted its stake in Heron Therapeutics by 11.4% in the second quarter. HighTower Advisors LLC now owns 16,584 shares of the biotechnology company’s stock valued at $231,000 after acquiring an additional 1,700 shares during the last quarter. 98.78% of the stock is currently owned by hedge funds and other institutional investors.

Heron Therapeutics (HRTX) opened at $18.42 on Tuesday. Heron Therapeutics has a 52 week low of $12.21 and a 52 week high of $19.55. The stock has a market cap of $1,000.00, a P/E ratio of -4.86 and a beta of 2.12. The company has a quick ratio of 2.02, a current ratio of 2.12 and a debt-to-equity ratio of 0.62.

Heron Therapeutics (NASDAQ:HRTX) last announced its quarterly earnings data on Monday, November 6th. The biotechnology company reported ($0.77) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.87) by $0.10. Heron Therapeutics had a negative net margin of 831.89% and a negative return on equity of 385.11%. The firm had revenue of $8.57 million for the quarter, compared to analysts’ expectations of $8.12 million. equities research analysts predict that Heron Therapeutics will post -3.39 EPS for the current year.

COPYRIGHT VIOLATION NOTICE: “Heron Therapeutics Sees Unusually High Options Volume (HRTX)” was reported by Watch List News and is the property of of Watch List News. If you are reading this piece of content on another site, it was copied illegally and republished in violation of US & international copyright and trademark laws. The correct version of this piece of content can be viewed at https://www.watchlistnews.com/heron-therapeutics-sees-unusually-high-options-volume-hrtx/1799119.html.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.

Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with Analyst Ratings Network's FREE daily email newsletter.